Clinical Guides
Lymphoma
A clinically focused, India-adapted guide to recognising, classifying and safely referring suspected lymphoma, with tissue-first diagnosis, subtype-specific management and explicit limits on international treatment pathways.
MedNext Academy | 14 min read
Lymphoma
A clinically focused, India-adapted guide to recognising, classifying and safely referring suspected lymphoma, with tissue-first diagnosis, subtype-specific management and explicit limits on international treatment pathways.
Summary
Lymphoma comprises malignant clonal disorders of lymphocytes and is not one disease. The clinically essential division is between Hodgkin lymphoma and the many mature B-cell, T-cell and natural-killer-cell non-Hodgkin lymphomas; each diagnosis is further defined by morphology, immunophenotype, genetics, anatomical pattern and clinical behaviour. An apparently indolent nodal illness, an aggressive abdominal mass and extranodal skin, gastrointestinal or central nervous system disease can therefore all be lymphoma. The word alone does not specify prognosis or treatment.
Persistent unexplained lymphadenopathy, constitutional symptoms, splenomegaly, cytopenias or an extranodal mass should prompt structured assessment. Tissue architecture matters: an excision biopsy is usually preferred when feasible, while a carefully planned image-guided core biopsy is appropriate when surgery is unsafe or the site is inaccessible. Fine-needle aspiration alone commonly cannot establish a complete lymphoma classification. The sample must reach an experienced haematopathology service with enough viable material for histology, immunohistochemistry, flow cytometry and selected molecular studies.
Staging follows histological confirmation unless an emergency demands simultaneous action. Imaging, laboratory results, performance status and subtype-specific prognostic factors guide a multidisciplinary plan. Some indolent lymphomas can be observed without immediate therapy; aggressive lymphomas require prompt curative-intent treatment when possible. Radiotherapy, immunochemotherapy, targeted medicines, cellular therapy and transplantation have subtype- and setting-specific roles. Infection prevention, fertility, tumour-lysis risk, transfusion support and survivorship belong in the original plan. This educational draft does not select a regimen and has been reviewed by the MedNext Clinical Team.
How Common Is It?
Lymphoma burden should be described with a named population, period and classification rather than one context-free number. Indian cancer registration is geographically incomplete and combines data from defined population-based registries with different age structures, referral patterns and case ascertainment. The ICMR-NCDIR National Cancer Registry Programme 2020 report is the appropriate national framework for understanding that limitation. A registry rate from one city or north-eastern district is not a national prevalence estimate, and a hospital series is especially vulnerable to referral selection.
Non-Hodgkin lymphoma collectively is more common than Hodgkin lymphoma, but grouping all subtypes hides major differences. Diffuse large B-cell lymphoma is a frequent aggressive subtype in adult clinical practice; follicular lymphoma, mantle-cell lymphoma, marginal-zone lymphoma, Burkitt lymphoma and peripheral T-cell lymphomas have different age distributions and geographical patterns. Hodgkin lymphoma has characteristic age and histological distributions. Children and adolescents have a different case mix from older adults, so adult incidence or treatment cannot be copied into paediatric counselling.
Recorded burden is shaped by access to biopsy, immunohistochemistry, flow cytometry, molecular testing and reliable death registration. Tuberculosis and other infections can delay or confuse diagnosis, while improved pathology may reclassify cases previously labelled nonspecifically. International cancer statistics may help compare broad patterns but cannot replace Indian registry evidence. For an individual patient, frequency does not determine probability: a persistent enlarging node, mediastinal mass, unexplained cytopenia or organ-threatening lesion deserves evaluation even where recorded local incidence is low. Conversely, most transient lymph-node enlargements are reactive. Good communication separates population burden from personal risk and avoids both alarm and false reassurance.
Risk Factors
Most people with lymphoma have no single identifiable preventable cause. Risk assessment should therefore guide context and selected testing rather than become a checklist that rules disease in or out. Immune dysregulation is important: untreated or advanced HIV, congenital immunodeficiency, autoimmune disease and immunosuppressive treatment after transplantation can increase the risk of particular lymphoid neoplasms. The magnitude and subtype vary, and stopping essential immunosuppression without specialist advice can be more dangerous than the theoretical risk.
Several infections have specific associations. Epstein-Barr virus participates in selected Hodgkin, Burkitt, post-transplant and T/NK-cell lymphomas; Helicobacter pylori drives many gastric mucosa-associated lymphoid tissue lymphomas; hepatitis C, human T-cell lymphotropic virus type 1 and human herpesvirus 8 relate to defined entities in particular populations. These associations do not mean that common infection symptoms imply lymphoma, and a positive test does not substitute for tissue diagnosis. HIV testing is clinically relevant in malignant lymphoma with consent and linkage to care. Prior chemotherapy or radiotherapy and a history of another malignancy can alter later risk.
Age, sex, ancestry and geography influence subtype distributions but should not be used as biological stereotypes. Family history slightly increases risk for some lymphoid malignancies, yet routine screening of healthy relatives with scans or blood tests is not established. Occupational and pesticide associations remain less specific than tissue and clinical evidence. Ask about immune disease, medicines, infection exposure, prior cancer treatment and family history, while also documenting node duration, systemic symptoms and growth. Risk factors modify pre-test probability; absence of every listed factor does not make persistent lymphadenopathy benign. Prevention centres on appropriate infection care and avoiding unnecessary immunosuppression, not on unproven diets, supplements or commercial screening panels.
Diagnosis
History
Document when the node or mass appeared, whether it is enlarging, painful or fluctuating, and whether it followed a local infection. Ask about measured fever, drenching night sweats, unintentional weight loss, pruritus, fatigue, recurrent infections, bruising, breathlessness, abdominal fullness, early satiety, bone pain and neurological symptoms. Record tuberculosis exposure, HIV risk without assumptions, autoimmune disease, transplantation, immunosuppressants, prior cancer therapy and current corticosteroid use. Establish performance status, pregnancy possibility, fertility priorities and barriers to reaching a diagnostic centre.
Examination
Assess physiological stability before a detailed cancer examination. Map nodal regions by site, size, consistency, mobility, tenderness and overlying skin; compare local drainage territories and look for generalized disease. Examine Waldeyer ring, skin, liver and spleen, and assess abdomen for a mass or ascites. Look for pallor, petechiae, infection, superior vena cava obstruction, pleural effusion and neurological deficit. A supraclavicular node, fixed progressive mass or unexplained splenomegaly raises concern, but no single physical sign establishes histology. Avoid repeated traumatic palpation or a prolonged empirical treatment trial.
Investigations
Obtain complete blood count with film, renal and liver profiles, calcium, lactate dehydrogenase and urate according to urgency; test for infections when clinically indicated. Normal blood counts do not exclude lymphoma. Plan biopsy with haematology, oncology, surgery, radiology and pathology so adequate unfixed and fixed tissue reaches the correct laboratories. Prefer excision for an accessible node; use generous image-guided cores when excision risk outweighs benefit. Histology integrates architecture, immunohistochemistry, flow cytometry and selected FISH or molecular tests. Stage with subtype-appropriate CT and, for FDG-avid disease when it changes care, PET-CT. Bone-marrow sampling is selective. Never start corticosteroids before biopsy unless an emergency specialist judges that immediate treatment outweighs the risk of obscuring diagnosis.
Differential Diagnosis
Reactive lymphadenopathy is common. Recent viral upper-respiratory illness, Epstein-Barr virus, cytomegalovirus, dental infection, skin infection and localized bacterial disease can produce tender nodes that regress. Tuberculous lymphadenitis is a major Indian differential, often chronic and painless, but constitutional symptoms, necrosis or matted nodes do not reliably distinguish it from lymphoma. Obtain appropriate microbiology and tissue; tuberculosis and lymphoma can coexist. HIV, toxoplasmosis, fungal infection and visceral leishmaniasis enter the differential according to exposure, immune status and geography.
Inflammatory and immune causes include systemic lupus erythematosus, rheumatoid disease, sarcoidosis, Kikuchi disease, IgG4-related disease and drug hypersensitivity. Medicines such as anticonvulsants can cause lymphadenopathy with systemic features. Metastatic carcinoma or melanoma may present in nodes, with the likely primary guided by drainage and pathology rather than age alone. Leukemia, plasma-cell neoplasia and myeloproliferative disorders can produce splenomegaly, cytopenias or lymphadenopathy. Castleman disease and histiocytic disorders require specialist pathology.
The differential also depends on site. A mediastinal mass may be lymphoma, thymic tumour, germ-cell tumour, thyroid disease or infection. An abdominal mass may arise from bowel, kidney, ovary, retroperitoneum or inflammatory tissue. Gastric lymphoma can resemble peptic or gastric epithelial disease; cutaneous lymphoma can mimic eczema or psoriasis. Node pain after alcohol is memorable but insensitive and nonspecific. A falling node after antibiotics or corticosteroids is not proof of a benign cause. Resolution with documented follow-up may support reactive disease, but persistence, progression, systemic illness, abnormal blood counts or clinicopathological discordance requires tissue-based reconsideration rather than serial empirical courses.
Management
Management starts only after the subtype, extent, pace, patient fitness and treatment goal are defined, except during a genuine emergency. A haematopathology review can change the diagnosis and should precede irreversible therapy. Discuss the case in a lymphoma multidisciplinary team with radiology, pathology, haematology/medical oncology, radiation oncology and relevant organ specialists. Staging systems summarize distribution, but histology and disease-specific prognostic indices often influence decisions more than stage alone. Baseline cardiac, renal, hepatic, infection and fertility assessment depends on the proposed treatment.
Observation is active management for selected asymptomatic indolent lymphomas without threatened organ function; it is not neglect and requires an agreed schedule and triggers. Localized entities may be treated with involved-site radiotherapy, infection eradication in selected MALT lymphoma, or limited systemic therapy. Aggressive B-cell and Hodgkin lymphomas often receive curative-intent combination treatment; T-cell, mantle-cell, Burkitt and lymphoblastic diseases need distinct specialist protocols. Relapsed disease may require salvage systemic therapy, autologous or allogeneic transplantation, bispecific antibodies, antibody-drug conjugates or cellular therapy where indicated and accessible. Names of rapidly changing products should never substitute for a current protocol and regulatory check.
Supportive care is integral: stratify tumour-lysis risk, prevent and treat infection, provide transfusion support, manage nausea, mucositis, pain and thrombosis, and preserve nutrition and mobility. Discuss sperm, oocyte or embryo preservation before gonadotoxic treatment when time and condition allow. Vaccination planning, hepatitis B reactivation prevention, antimicrobial prophylaxis and irradiated blood-component requirements are regimen-specific. Palliative care can accompany disease-directed therapy for symptom control and decisions. After treatment, use response assessment appropriate to the subtype and avoid routine imaging in asymptomatic remission where evidence does not support it.
Prescribing Information
Systemic lymphoma therapy is specialist prescribing with narrow safety margins. Before any regimen, confirm pathology, body surface area or protocol weight, performance status, pregnancy status where relevant, blood counts, kidney and liver function, cardiac risk, infection screening, interactions and supportive-care orders. Anti-CD20 antibodies can reactivate hepatitis B; screening and antiviral management must follow a current haematology and hepatology pathway. Infusion reactions, cytopenias and infections require planned observation and rapid-access instructions. Live vaccines are generally avoided during significant immunosuppression, while timing of inactivated vaccines requires specialist advice.
Many combination regimens include an anthracycline, alkylating agent, vinca alkaloid and corticosteroid, but agents cannot be swapped casually. Anthracyclines carry cumulative cardiotoxicity and vesicant risk. Vinca alkaloids cause neuropathy, constipation and dangerous interactions; vincristine must never be administered intrathecally. Alkylating agents can impair fertility and marrow reserve. High-dose corticosteroids can cause hyperglycaemia, infection, mood change, gastrointestinal complications and diagnostic masking. Selected drugs require mesna, hydration, leucovorin rescue, therapeutic monitoring or central-line safeguards.
Tumour lysis may begin spontaneously or after treatment. Risk-based hydration, urate-lowering therapy and frequent potassium, phosphate, calcium, urate, creatinine and fluid monitoring must be protocolled; established severe syndrome needs monitored hospital care, not oral reassurance. Growth factors, antiemetics, antimicrobial prophylaxis and thromboprophylaxis are chosen by regimen and patient risk. Verify current Indian regulator status, institutional formulary and acquisition cost for targeted or cellular therapy; foreign approval is not Indian approval. Patients should receive a treatment calendar, fever threshold, 24-hour contact, missed-dose advice and interaction review including complementary products. This guide intentionally gives no doses because safe dosing depends on exact histology, protocol, organ function and cycle.
When to Refer
Refer persistent, unexplained or progressive lymphadenopathy for specialist assessment when duration, size, location, systemic symptoms, abnormal blood counts, splenomegaly or imaging makes simple observation unsafe. An accessible concerning node should enter a planned biopsy pathway rather than undergo repeated fine-needle aspirations. Refer an unexplained mediastinal, retroperitoneal or extranodal mass to a centre that can coordinate safe image-guided sampling and preserve material for complete classification. Provide prior imaging, blood trends, infection tests, medicines and any pathology blocks or slides.
Urgency rises with rapid growth, significant B symptoms, cytopenias, organ compromise, very high lactate dehydrogenase or urate, renal dysfunction or suspected aggressive histology. Same-day haematology/oncology discussion is appropriate when tumour lysis is evolving, blasts appear, a bulky mass threatens airway or vessels, or neurological findings suggest cord or central nervous system involvement. Suspected paediatric lymphoma belongs in a paediatric oncology service; young adults may benefit from age-appropriate pathways. Pregnancy requires obstetric and haematology-oncology coordination without assuming that all imaging or treatment must wait.
Confirmed lymphoma requires multidisciplinary review. Add infectious diseases for HIV, hepatitis or complex infection; radiation oncology for potentially local treatment; fertility services before gonadotoxic therapy; and transplantation or cellular-therapy services early when candidacy may matter. Dietetics, physiotherapy, psychology, social work and palliative care are appropriate according to need. In India, referral quality includes practical transfer: name the receiving centre, state urgency, send tissue requirements before biopsy, confirm affordability and travel, and give instructions for deterioration. A referral is incomplete if the patient leaves with only the phrase ‘rule out lymphoma’ and no diagnostic owner.
Red Flags
Stridor, orthopnoea, hypoxia, facial or upper-limb swelling, venous distension, syncope or inability to lie flat with a mediastinal mass may indicate airway compromise or superior vena cava obstruction. Keep the patient in the position they tolerate, seek urgent anaesthetic and oncology input and avoid unplanned sedation or supine procedures. New weakness, sensory change, sphincter disturbance or severe focal back pain suggests spinal cord or cauda equina compression and requires emergency imaging and specialist treatment.
Tumour lysis syndrome presents through a dangerous combination of rising potassium, phosphate and urate, falling calcium, acute kidney injury, arrhythmia, seizure or fluid imbalance. It can precede therapy in rapidly proliferative lymphoma. Fever with hypotension, confusion, rigors or neutropenia is sepsis until proved otherwise. Bleeding, severe symptomatic anaemia or profound thrombocytopenia needs urgent haematology support. Acute abdominal pain, guarding, obstruction, intussusception or perforation can complicate gastrointestinal lymphoma, particularly around treatment.
Rapidly enlarging painful nodes with systemic toxicity may represent aggressive lymphoma, infection or haemorrhage and should not wait for a routine clinic. Severe headache, focal neurology, cranial-nerve dysfunction or altered behaviour can signal central nervous system disease or infection. During therapy, chest pain, dyspnoea, reduced urine output, uncontrolled vomiting, diarrhoea, mucositis preventing hydration, jaundice or new rash may reflect toxicity or opportunistic infection. Red flags determine urgency, not histology. Stabilize airway, breathing and circulation, obtain time-critical investigations without delaying treatment, and contact the relevant emergency, haematology and oncology teams. Do not give empirical corticosteroids solely to shrink a mass before biopsy unless the responsible emergency specialist documents why immediate benefit outweighs diagnostic harm.
Indian Clinical Context
India has major variation in access to excision biopsy, expert haematopathology, flow cytometry, FISH, PET-CT, radiotherapy, transplantation and newer immune therapies. The ICMR 2016 high-grade non-Hodgkin lymphoma consensus supplies Indian clinical framing and emphasizes combined clinical, morphological, immunological and molecular diagnosis, but it reviewed older evidence and cannot be treated as a current drug formulary. The ICMR immunophenotyping SOP remains useful for specimen handling, panel principles and quality control while openly acknowledging that technology and classification evolve.
Tuberculosis is a common diagnostic competitor. Geography is not a laboratory result: do not start prolonged antituberculous therapy for unexplained nodes without an appropriate microbiological and pathological plan, and do not dismiss infection once lymphoma is found. A fresh sample may need separate routing for flow cytometry and microbiology; coordinate before fixation. Poor tissue handling can force another procedure and delay treatment. When advanced molecular tests are unavailable, document what could not be established and seek reference review if the result would change therapy.
current guidelines was reviewed in June 2026 and offers a current UK comparator for biopsy and several non-Hodgkin pathways, but public health commissioning, technology appraisals and surveillance arrangements do not govern India. Apply current Indian approval, local protocol and patient-specific access. Out-of-pocket cost, distance, accommodation, blood-product supply and caregiver work loss materially affect feasibility. Offer transparent choices without presenting a less expensive evidence-based regimen as inferior care or an unavailable product as the only acceptable option. Consent should use the preferred language and include fertility, infection, late effects and financial toxicity. No single national incidence figure, uniform waiting-time pathway or universal treatment availability is claimed.
NMC Competency Mapping
The NMC CBME Curriculum 2024 provides direct pathology anchors. PA19.1 requires learners to enumerate causes and differentiating features of lymphadenopathy. PA19.3 covers the pathogenesis, pathology and distinguishing features of Hodgkin and non-Hodgkin lymphoma, while PA19.6 includes recognition of Hodgkin lymphoma in gross and microscopic material. PA18.2 on acute and chronic leukaemia helps learners understand the overlap between lymphoblastic lymphoma/leukaemia and mature lymphoid diseases. General neoplasia competencies PA6.1 to PA6.5 support tumour biology, spread, host effects, carcinogenesis and laboratory diagnosis.
An undergraduate should take a structured node and constitutional history, map lymphadenopathy, examine spleen and identify physiological emergencies. They should construct infectious, immune, metastatic and haematological differentials, with particular attention to tuberculous lymphadenitis in India. They should explain why node architecture and an adequate biopsy matter, distinguish Hodgkin from non-Hodgkin patterns at a principles level, and connect morphology to immunophenotype without claiming to sign out pathology.
Teaching should integrate pathology, medicine, surgery, microbiology, paediatrics, radiology and pharmacology. A useful assessment asks the learner to choose and route a biopsy, recognize a mediastinal emergency or interpret a clinicopathological mismatch rather than recite every CD marker. Learners should know broad Ann Arbor staging concepts, tumour lysis, febrile neutropenia and the difference between observation of indolent disease and delayed care of aggressive disease. Curriculum mapping does not authorize independent biopsy, chemotherapy, radiotherapy or transplantation decisions. Skills remain consented and supervised, and rapidly changing regimens should be assessed through treatment principles rather than memorized product lists.
Key Exam Pearls for NEET PG
Lymphoma is a clonal lymphoid malignancy classified by lineage, maturation, morphology, immunophenotype, genetics and clinical setting. Hodgkin lymphoma classically spreads contiguously and has diagnostic Reed-Sternberg-type cells in an appropriate background; non-Hodgkin lymphomas more often show non-contiguous and extranodal disease, but these are tendencies rather than absolute rules. B symptoms are otherwise unexplained fever above 38 degrees Celsius, drenching night sweats and unintentional loss of more than 10 percent of body weight within six months. Lactate dehydrogenase reflects turnover and prognosis in context, not diagnosis.
Excision biopsy is preferred for an accessible suspicious node because architecture is critical. Fine-needle aspiration alone is usually insufficient for definitive classification; a core biopsy is the practical alternative when excision is unsafe. Send fresh tissue correctly for flow cytometry when required and fixed tissue for histology. Do not destroy diagnostic yield with empirical corticosteroids before biopsy unless treating an emergency. Stage FDG-avid subtypes with PET-CT when the result changes management; not every lymphoma needs identical imaging or bone-marrow biopsy.
Indolent does not mean benign, and advanced stage does not always mean incurable. Asymptomatic low-burden indolent disease may be observed, whereas diffuse large B-cell and Burkitt lymphomas require prompt systemic treatment. Gastric MALT lymphoma may regress after Helicobacter pylori eradication. Tumour lysis, superior vena cava obstruction, airway compression, cord compression, sepsis and bowel perforation are emergencies. HIV and hepatitis testing can alter safety and treatment. In India, tuberculosis is a vital differential but requires evidence; it may coexist with lymphoma. For NMC retain PA19.1, PA19.3 and PA19.6, and link them to adequate tissue, Hodgkin/non-Hodgkin differentiation and safe referral rather than independent regimen selection.
Frequently Asked Questions
Does every persistent enlarged lymph node mean that the patient has lymphoma?
No. Reactive viral or bacterial disease, tuberculosis, HIV, autoimmune conditions, medicines and metastatic cancer are important alternatives. Concern rises with progression, supraclavicular location, systemic symptoms, splenomegaly, abnormal blood counts or unexplained persistence. A clinician should document follow-up and arrange appropriately planned tissue diagnosis when the pattern remains suspicious rather than infer lymphoma from touch or imaging alone.
Why is an excision biopsy often preferred over a needle aspiration for suspected lymphoma?
Lymphoma classification depends on lymph-node architecture as well as cell morphology, immunophenotype and genetics. Excision usually supplies enough intact tissue for these assessments. A carefully planned core biopsy is reasonable when excision is risky or the site is inaccessible, but fine-needle aspiration alone frequently cannot define the complete entity. The biopsy route should be agreed with pathology before tissue is taken.
Can an indolent lymphoma be safely observed without immediate anticancer treatment?
Yes, selected asymptomatic indolent lymphomas without threatened organ function can enter structured observation because immediate treatment may not improve outcome and can cause harm. Observation needs a confirmed subtype, staging, an agreed follow-up schedule, clear treatment triggers and rapid reassessment for new symptoms. It is different from leaving an unbiopsied or rapidly progressive mass unattended.
Can UK lymphoma guidance be applied directly to treatment decisions in India?
It can inform clinical reasoning, biopsy principles and evidence review, but it is not Indian policy. Medicine approval, funding, pathology capacity, PET-CT, radiotherapy, transplantation and follow-up systems differ. Current Indian regulation, institutional protocols, multidisciplinary review and patient access must govern care. Older ICMR material adds local context but also requires reconciliation with newer classification and treatment evidence.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic